Yára Dadalti Fragoso
A5020111272- Multiple Sclerosis Research Studies
- Migraine and Headache Studies
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Reproductive System and Pregnancy
- Sympathectomy and Hyperhidrosis Treatments
- Acute Lymphoblastic Leukemia research
- Ophthalmology and Eye Disorders
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Autoimmune and Inflammatory Disorders Research
- Trigeminal Neuralgia and Treatments
- SARS-CoV-2 and COVID-19 Research
- Systemic Sclerosis and Related Diseases
- Systemic Lupus Erythematosus Research
- Long-Term Effects of COVID-19
- Rheumatoid Arthritis Research and Therapies
- Sphingolipid Metabolism and Signaling
- T-cell and Retrovirus Studies
- Pregnancy and Medication Impact
- Ocular Diseases and Behçet’s Syndrome
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cerebral Venous Sinus Thrombosis
- Biochemical effects in animals
- Neurological Disorders and Treatments
- Neurological Complications and Syndromes
Universidade Metropolitana de Santos
2016-2025
Universidade de São Paulo
2016-2023
The University of Queensland
2023
QIMR Berghofer Medical Research Institute
2023
University of Tasmania
2023
University of Aberdeen
1992-2023
The University of Melbourne
2022-2023
Barwon Health
2023
University of Newcastle Australia
2023
Multiple Sclerosis Research Institute
2020-2023
Estimates of the spectrum and frequency pathogenic variants in Parkinson's disease (PD) different populations are currently limited biased. Furthermore, although therapeutic modification several genetic targets has reached clinical trial stage, a major obstacle conducting these trials is that PD patients largely unaware their status and, therefore, cannot be recruited. Expanding number investigated PD-related genes including related to disorders with overlapping features large,...
Importance Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS). Rituximab, chimeric anti-CD20 agent, is often prescribed as an off-label alternative to ocrelizumab. Objective To evaluate whether effectiveness rituximab noninferior ocrelizumab MS. Design, Setting, Participants This was observational cohort study...
Background: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. Objective: aim of this study was determine the demographic, clinical and paraclinical features that influence sclerosis. Methods: Patients with adult-onset relapsing–remitting at least four recorded disability scores were selected MSBase, a global observational cohort. objectively defined evaluated time points per patient using multivariable marginal Cox...
The MuSC-19 project is an Italian cohort study open to international partners that collects data on multiple sclerosis (MS) patients with COVID-19. During the second wave of pandemic, serological tests became routinely available.To evaluate seroprevalence anti-SARS-CoV-2 antibodies according use disease-modifying therapy (DMT) in a subset included set who had undergone test.We evaluated association between positive test results and time elapsed since infection onset, age, sex, Expanded...
<h3>Background and Objectives</h3> To evaluate the rate of return disease activity after cessation multiple sclerosis (MS) disease-modifying therapy. <h3>Methods</h3> This was a retrospective cohort study from 2 large observational MS registries: MSBase OFSEP. Patients with relapsing-remitting who had ceased therapy were followed up for subsequent 12 months included in analysis. The primary outcome annualized relapse discontinuation stratified by patients did, did not, commence secondary...
Patients with the 'aggressive' form of multiple sclerosis accrue disability at an accelerated rate, typically reaching Expanded Disability Status Score (EDSS) ≥ 6 within 10 years symptom onset. Several clinicodemographic factors have been associated aggressive sclerosis, but less research has focused on clinical markers that are present in first year disease. The development early predictive models is essential to optimize treatment this subtype. We evaluated whether patients who will...
We report on nine patients (eight cases of MS and one case NMOSD) who presented a disease relapse in close temporal association with their first AZD1222 vaccination dose against COVID-19. These had been stable for median period six years, no evidence activity change medication. After 13 days (7 to 25 days) from vaccination, they developed new increased disability lesions magnetic resonance imaging. Although this may be rare, it might an adverse event AZD1222.
The severity of multiple sclerosis (MS) varies widely among individuals. Understanding the determinants this heterogeneity will help clinicians optimize management MS. aim study was to investigate association between latitude residence, UV B radiation (UVB) exposure, and MS.This observational used MSBase registry data. included patients met 2005 or 2010 McDonald diagnostic criteria for MS had a minimum dataset recorded in (date birth, sex, clinic location, date symptom onset, disease...
The idiopathic inflammatory demyelinating disease (IIDD) spectrum has been investigated among different populations, and the results have indicated a low relative frequency of neuromyelitis optica (NMO) multiple sclerosis (MS) cases in whites (1.2%-1.5%), increasing Mestizos (8%) Africans (15.4%-27.5%) living areas MS prevalence. South America (SA) was colonized by Europeans from Iberian Peninsula, their miscegenation with natives slaves resulted significant racial mixing. current study...
Abstract In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies reduce activity, the time required to attain maximal effect unclear. this study we aimed develop a method that allows identification manifest fully and clinically sclerosis treatments (‘therapeutic lag’) on clinical activity represented relapses progression-of-disability events. Data from two registries, MSBase (multinational) OFSEP (French), were used....
We assessed the efficacy and safety of oral single doses 0.5 1 g metamizol vs. acetylsalicylic acid (ASA) in 417 patients with moderate episodic tension-type headache included a randomized, double-blind, placebo- active-controlled, parallel, multicentre trial. Eligibility criteria 18–65 years age, history at least two episodes per month 3 months prior to enrolment, successful previous pain relief non-opioid analgesic. Treatment arms were ( n = 102), 108), ASA 102) placebo 105). The analgesic...
Retinoic acid, the active form of nutrient vitamin A, regulates several facets neuronal plasticity in hippocampus, including neurogenesis and synaptic strength, acting via specific retinoic acid receptors (RARs). Essential for conversion A to is enzyme retinaldehyde dehydrogenase (RALDH) rodent hippocampus this only present adjacent meninges where it must act as a locally released paracrine hormone. Little known though about expression RALDHs RARs human hippocampus. This study confirms that...
[Purpose] Present study aimed to evaluate the relationship between sleep bruxism and headache in school children. [Subjects Methods] This was conducted with 103 children aged 3–6 years. The exclusion criteria were early tooth loss, dental appliance used, physical or psychological limitations, chronic disease continuous medication. Sleep diagnosed based on an indication by parents of occurrence teeth clenching/grinding incisor/occlusal wear, following American Academy Medicine. quality...